NC
URGN icon

Nexthera Capital’s UroGen Pharma URGN Stock Holding History

Nexthera Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$6.36M Buy
176,866
+44,277
+33% +$1.63M 5.29% 11
2019
Q1 		$4.9M Buy
+132,589
New +$5.56M 5.94% 6

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Nexthera Capital's URGN Position: Q2 2019 in Review

Nexthera Capital increased its UroGen Pharma (URGN) stake by 33% in Q2 2019, buying an estimated $1.63M and bringing the position to 176,866 shares worth $6.36M. The position accounts for 5.29% of the portfolio, ranked #11.

Nexthera Capital first reported a position in URGN in Q1 2019 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2019.

  • Nexthera Capital held 176,866 shares of UroGen Pharma worth $6.36M as of Q2 2019.
  • Nexthera Capital bought 44,277 UroGen Pharma shares in Q2 2019, an estimated $1.63M.
  • UroGen Pharma made up 5.29% of Nexthera Capital's portfolio in Q2 2019, its #11 holding.
  • Nexthera Capital first reported a position in UroGen Pharma in Q1 2019 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.